Biohaven Ltd.

BHVN's 20.5% short interest is extraordinarily high for a biotech with $1.5B market cap, suggesting significant skepticism about its fundamentals or pipeline. The stock sits at RSI 60.7—approaching overbought territory—yet trades below 52-week highs, indicating recent momentum without full euphoria. The absence of a P/E ratio signals the company remains unprofitable, a common state for pharmaceutical developers. This setup hints at potential squeeze dynamics if clinical or commercial news catalyzes short covering, though the elevated short ratio may also reflect justified caution about execution risk or pipeline viability. The tension between momentum and profitability concerns creates elevated volatility risk.